# EBR Systems

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ebr-systems

- Industry: Medical Devices & Equipment
- Headquarters: Sunnyvale, US
- Website: www.ebrsystemsinc.com
- Total disclosed funding: $100M
- Latest round: Series E (Apr 8, 2015)
- Investors on record: 7

## About

EBR Systems, Inc. is a medical technology company focused on developing innovative cardiac rhythm management solutions, particularly the leadless WiSE Cardiac Resynchronization Therapy System, aimed at enhancing patient care and treatment efficacy.Founded in 2003, EBR Systems, Inc. specializes in cardiac rhythm management technologies. The company is headquartered in Sunnyvale, US, and has evolved its business strategy to focus on leadless pacing solutions. Rick Riley established the company, which has secured funding through multiple rounds, culminating in an IPO on November 24, 2021, raising AUD 110.000 mn, the total amount raised is also AUD 110.000 mn.EBR Systems, Inc. specializes in innovative cardiac rhythm management solutions, most notably the WiSE Cardiac Resynchronization Therapy (CRT) System. This groundbreaking product is recognized as the only leadless left ventricular endocardial pacing (LVEP) device, designed to address the limitations associated with traditional CRT methods. The ultra-compact device, measuring the size of a grain of rice, eliminates the need for lead-based pacing systems, thereby providing a more physiological approach to cardiac pacing. The WiSE CRT System coordinates therapy with existing pacing devices, allowing for optimized patient care across various clinical settings. EBR Systems targets healthcare professionals, hospitals, and clinics, with products available in markets including North America, Europe, and select regions in Asia-Pacific.EBR Systems generates revenue primarily through direct sales of its WiSE CRT System and related services to healthcare providers. The company operates on a B2B transaction structure, engaging with hospitals and clinics that utilize the WiSE technology for cardiac resynchronization. Transactions typically involve initial equipment purchases followed by agreements for ongoing support and maintenance, ensuring optimal functionality of the device. As a part of its revenue model, EBR Systems may also explore partnerships with medical device distributors to enhance market reach. The flagship WiSE CRT System not only serves as a cornerstone of the product portfolio but also positions the company as a leader in advancing cardiac therapy solutions.Following its IPO on November 24, 2021, EBR Systems, Inc. plans to utilize the AUD 110.000 mn raised to complete the enrollment of its pivotal SOLVE CRT clinical trial and prepare for the commercialization of the WiSE Cardiac Resynchronization Therapy (CRT) System. The company is focusing on expanding its market presence in North America, Europe, and select regions in Asia-Pacific, aiming to enhance accessibility to its innovative solutions in the cardiac therapy space.

## Funding rounds

- Series E, Apr 8, 2015, $20M — Delphi Ventures, St. Paul Venture Capital, SV Health Investors, Split Rock Partners, Emergent Medical Ventures
- Series E, Jul 15, 2014, $19M — Delphi Ventures, SV Health Investors
- Series D, Feb 10, 2011, $5M — Delphi Ventures, St. Paul Venture Capital, De Novo Ventures, SV Health Investors, Split Rock Partners
- Series C, Jun 12, 2008, $35M — Delphi Ventures, Frazier Healthcare Partners, De Novo Ventures, SV Health Investors, Split Rock Partners
- Series B, Dec 8, 2005, $21M — Frazier Healthcare Partners, St. Paul Venture Capital, De Novo Ventures, SV Health Investors, Split Rock Partners

## Investors

- Frazier Healthcare Partners (https://capitalatlas.ai/funds/frazier-healthcare-partners) — Series B, Series C
- St. Paul Venture Capital (https://capitalatlas.ai/funds/st-paul-venture-capital) — Series B, Series D, Series E
- De Novo Ventures (https://capitalatlas.ai/funds/de-novo-ventures) — Series B, Series C, Series D
- SV Health Investors (https://capitalatlas.ai/funds/sv-health-investors) — Series B, Series C, Series D, Series E
- Split Rock Partners (https://capitalatlas.ai/funds/split-rock-partners) — Series B, Series C, Series D, Series E
- Delphi Ventures (https://capitalatlas.ai/funds/delphi-ventures) — Series C, Series D, Series E
- Emergent Medical Ventures (https://capitalatlas.ai/funds/emergent-medical-ventures) — Series E